



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/653,812	09/01/2000	Haig H. Kazazian JR.	9596-23U3	6101
9629	7590	12/17/2001		
MORGAN, LEWIS & BOCKIUS 1800 M STREET NW WASHINGTON, DC 20036-5869			EXAMINER	
			BAKER, ANNE MARIE	
		ART UNIT	PAPER NUMBER	
		1632		
DATE MAILED: 12/17/2001				

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	09/653,812	KAZAZIAN ET AL.
	Examiner Anne-Marie Baker	Art Unit 1632

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 01 September 2000.

2a) This action is FINAL. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 34-49 is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) 34-49 is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on 01 September 2000 is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

11) The proposed drawing correction filed on _____ is: a) approved b) disapproved by the Examiner.
If approved, corrected drawings are required in reply to this Office action.

12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some * c) None of:

1. Certified copies of the priority documents have been received.

2. Certified copies of the priority documents have been received in Application No. _____.

3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).

a) The translation of the foreign language provisional application has been received.

15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

1) Notice of References Cited (PTO-892)

2) Notice of Draftsperson's Patent Drawing Review (PTO-948)

3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____.

4) Interview Summary (PTO-413) Paper No(s) _____.

5) Notice of Informal Patent Application (PTO-152)

6) Other: _____

Application/Control Number: 09/653,812

Page 2

Art Unit: 1632

DETAILED ACTION

The preliminary amendment filed September 1, 2000 (Paper No. 5) has been entered. Claims 1-33 have been cancelled. Claims 34-49 have been newly added.

Accordingly, Claims 34-49 are pending in the instant application.

Oath/Declaration

The oath or declaration is defective. A new oath or declaration in compliance with 37 CFR 1.67(a) identifying this application by application number and filing date is required. See MPEP §§ 602.01 and 602.02.

The oath or declaration is defective because:

It does not state that the person making the oath or declaration has reviewed and understands the contents of the specification, including the claims, as amended by any amendment specifically referred to in the oath or declaration.

A preliminary amendment was filed September 1, 2000 in this divisional application. The declaration does not specifically refer to the amendment. A newly executed declaration is required.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Art Unit: 1632

Claims 34-49 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

The claims are directed to a non-human transgenic mammal comprising a specific retrotransposon as well as a sperm cell obtained from a male non-human transgenic mammal comprising said specific retrotransposon.

The specification fails to provide an enabling disclosure for the claimed transgenic animal because the phenotype of a transgenic animal is unpredictable

The specification fails to provide an enabling disclosure for making and using any and all non-human transgenic animals of the type claimed because the specification does not teach how to use a transgenic animal that does not exhibit a specific transgene-dependent phenotype. In the absence of specific guidance one skilled in the art would not have been able to use other transgenic animals of the type claimed. The claim encompasses transgenic animals that do not exhibit any specific transgene-dependent phenotypic alteration, but the specification does not teach how to use animals that do not exhibit a specific phenotype. The specification does not provide specific guidance for making and using any species of transgenic mammal as claimed. Furthermore, the claim encompasses transgenic animals that exhibit an undisclosed and unspecified transgene-dependent phenotypic alteration, but the specification does not teach how to use any animal exhibiting any transgene-dependent phenotypic alteration.

However, the specification is not enabling for any non-human mammal because the transgenic art is highly unpredictable, as discussed below. It is not a routine matter to obtain expression of a transgene at the requisite level at the appropriate time in the desired tissue to produce a desired effect, in any and all animal

Art Unit: 1632

species. The specification only teaches what is intended to be done and how it is intended to work but does not actually teach how to do what is intended.

The specification fails to provide an enabling disclosure for the preparation of any species of transgenic animal of the type claimed because the phenotype of a transgenic animal cannot be predicted. The specification does not teach how to use the claimed transgenic animals because their use is dependent upon having a specific transgene-dependent phenotypic alteration, but the specification does not teach a specific phenotype for the claimed animals. No guidance is provided with respect to how one would have prepared any and all transgenic animals exhibiting the desired transgene-dependent phenotypic alteration. The mere capability to perform gene transfer in any given species is not enabling for the claimed transgenic animals because the desired phenotype cannot be predictably achieved simply by introducing a transgene construct of the type recited in the claim. While gene transfer techniques are well-developed for a number of species, especially the mouse, methods for achieving the desired level of transgene expression in appropriate tissues are less well-established. The introduction of DNA into the mammalian genome can ordinarily be achieved most reliably by microinjection or retrovirus-mediated gene transfer. However, the state of the art for transgenics is unpredictable because the method of gene transfer typically relies on random integration of the transgene construct. Insertional inactivation of endogenous genes and position effects (see Wall, 1996, p. 61, paragraph 3) can dramatically influence the phenotype of the resultant transgenic animal. Integration of the transgene near highly active genes or, alternatively, in a transcriptionally inactive region, can influence its level of expression. Furthermore, expression of the transgene and the effect of transgene expression on the phenotype of the transgenic animal depends on the particular gene construct used, to an unpredictable extent. The particular genetic elements required for appropriate expression varies from species to species. Thus, a construct that confers the desired phenotype

Art Unit: 1632

in a mouse will not necessarily achieve the same result in a rat. Wall (1996) reports that our lack of understanding of essential genetic control elements makes it difficult to design transgenes with predictable behavior (p. 61, paragraph 3). This is especially relevant for species in which genetic studies are less advanced than in the mouse. Thus, the species-specific requirements for transgene design introduces an additional level of unpredictability associated with the development of transgenic animals. Furthermore, there are inherent physiological differences between mice, pigs, cows, sheep, etc. that can affect the phenotype in an unpredictable manner. In the absence of specific guidance, the production of the desired phenotypic alteration resulting from the introduction of a nucleic acid construct as recited in the claim, is highly unpredictable. In the absence of specific guidance, one skilled in the art would not be able to produce a transgenic animal of any species exhibiting a specific phenotype, without undue experimentation.

The species-specific requirements for transgene design are not clearly understood. Examples in the literature aptly demonstrate that even closely related species carrying the same transgene construct can exhibit widely varying phenotypes. For example, several animal models of human diseases have relied on transgenic rats when the development of mouse models was not feasible. Mullins et al. (1990) produced outbred Sprague-Dawley x WKY rats with hypertension caused by expression of a mouse *Ren-2* renin transgene. Hammer et al. (1990) describe spontaneous inflammatory disease in inbred Fischer and Lewis rats expressing human class I major histocompatibility allele HLA-B27 and human β_2 -microglobulin transgenes. Both investigations were preceded by the failure to develop human disease-like symptoms in transgenic mice (Mullins et al., 1989; Taurog et al., 1988) expressing the same transgenes that successfully caused the desired symptoms in transgenic rats.

Art Unit: 1632

Given that specific phenotypic alterations cannot be predictably achieved by merely transferring a gene of interest into an animal, specific guidance must be provided in the disclosure to enable the instant invention. The specification must teach those skilled in the art how to make and use the full scope of the claimed invention without undue experimentation. The claim covers any transgenic mammal harboring a transgene construct of the type recited in the claim, but the specification does not enable such animals nor the use of such animals. In the absence of an enabling disclosure for the full scope of transgenic animals, exhibiting an appropriate phenotype, undue experimentation would have been required to make and use the full scope of claimed animals.

Conclusion

No claims are allowable.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Anne-Marie Baker whose telephone number is (703) 306-9155. The examiner can normally be reached Monday through Thursday and alternate Fridays from 10:00 AM to 7:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Karen Hauda, can be reached on (703) 305-6608. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-8724.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the patent analyst, Kay Pinkney, whose telephone number is (703) 305-3553.

Anne-Marie Baker, Ph.D.

Anne-Marie Baker
ANNE-MARIE BAKER
PATENT EXAMINER